Dextrose Injections Outperform Hyaluronic Acid for Knee Osteoarthritis Pain
A 2025 mini-review synthesizes RCTs and meta-analyses showing hypertonic dextrose prolotherapy rivals or beats standard OA injections.
Summary
Hypertonic dextrose prolotherapy (DPT) involves injecting 12.5–25% dextrose solutions into arthritic joints to trigger a controlled inflammatory healing cascade. This 2025 mini-review from Frontiers in Endocrinology synthesizes evidence from randomized controlled trials and meta-analyses covering nearly 7,000 patients. DPT activates fibroblasts, stimulates collagen synthesis, and recruits growth factors including TGF-β, PDGF, and IGF. Clinical data show DPT reduces pain and improves function comparably or superiorly to hyaluronic acid, and when combined with physical therapy, outperforms PRP, HA, and physiotherapy alone. A key meta-analysis of 14 RCTs found dose- and time-dependent benefits with a strong safety profile. Standardization of protocols and long-term trials remain the primary unmet needs.
Detailed Summary
Osteoarthritis affects over 600 million people globally and is projected to exceed 1.1 billion cases by 2050, yet current treatments — NSAIDs, corticosteroids, and hyaluronic acid injections — address symptoms without modifying disease progression. This 2025 mini-review in Frontiers in Endocrinology by Huang and Cai synthesizes the growing body of clinical and mechanistic evidence for hypertonic dextrose prolotherapy (DPT) as a regenerative alternative, drawing on RCTs, meta-analyses, and network meta-analyses involving thousands of knee OA patients.
Biologically, DPT works by injecting 12.5–25% dextrose solutions into or around the affected joint, inducing a localized, controlled inflammatory response. This recruits key growth factors — transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF) — which drive fibroblast activation, collagen fiber deposition, chondrocyte anabolism, and proteoglycan synthesis. The net effect is extracellular matrix remodeling and tissue regeneration rather than mere symptom suppression.
A pivotal meta-analysis of 14 RCTs (n=978 patients) found that DPT significantly reduced pain and improved physical function and quality of life versus placebo. Critically, outcomes were dose- and time-dependent: more injections and longer follow-up correlated with better results. Combined intra-articular plus extra-articular injections outperformed intra-articular injections alone. Dropout rates were lower in DPT groups, and no significant increase in adverse events was observed. A concentration-comparison RCT found that 20% DPT produced the greatest improvements in VAS and WOMAC scores and knee flexion versus 5% and 10% concentrations, though all outperformed exercise-only controls.
Head-to-head comparisons reveal a nuanced picture. Against normal saline, DPT produced superior WOMAC pain, function, and composite scores plus EuroQol-5D improvements sustained at 52 weeks. Against hyaluronic acid, results were mixed: one study showed DPT significantly reduced urinary CTX-II (a cartilage degradation biomarker) and outperformed HA on pain and function, while another found HA superior for symptom relief. A large network meta-analysis of 80 RCTs (n>6,900) found DPT combined with physical therapy (PT) achieved the highest pain reduction (SMD = -2.54) and global function restoration (SMD = 2.28) of any regimen tested, surpassing PRP+PT, HA+DPT, and monotherapies. Against standalone PRP, DPT was slightly inferior in a small early-stage KOA trial, but superior when combined with PT in broader populations.
The review also highlights injection site as a meaningful variable. A three-arm RCT comparing intra-articular, peri-articular perineural, and combined injections found the combination produced the lowest VAS and WOMAC scores at 4 and 8 weeks, with higher pressure pain threshold values suggesting superior nerve sensitization relief. These findings suggest that multimodal DPT protocols targeting both intra- and peri-articular structures may maximize therapeutic benefit.
Despite promising results, the authors emphasize significant caveats. Heterogeneity in dextrose concentrations (5–25%), injection frequencies, target sites, and follow-up durations makes cross-study comparisons difficult. Most trials are short-term, and few include structural imaging endpoints to confirm cartilage preservation. Risk of bias remains a concern across included studies. The authors call for large, well-powered RCTs with standardized protocols, long-term follow-up, and biomarker endpoints to definitively establish DPT's role in OA management.
Key Findings
- Meta-analysis of 14 RCTs (n=978) found DPT significantly reduced pain and improved function vs. placebo, with dose- and time-dependent effects favoring more injections and longer follow-up
- 20% dextrose concentration produced the greatest VAS and WOMAC score improvements and knee flexion gains compared to 5% and 10% concentrations, all outperforming exercise-only controls
- Network meta-analysis of 80 RCTs (n>6,900) found DPT+physical therapy achieved the highest pain reduction (SMD = -2.54) and global function restoration (SMD = 2.28) of all regimens tested
- DPT reduced urinary CTX-II (cartilage degradation biomarker) more substantially than hyaluronic acid, suggesting potential disease-modifying rather than purely symptomatic effects
- Combined intra-articular + peri-articular DPT produced lower VAS and WOMAC scores at 4 and 8 weeks versus either injection site alone, with higher pressure pain threshold values
- DPT benefits vs. normal saline persisted for up to 52 weeks with no reported adverse events and high patient satisfaction in a Hong Kong RCT
- Dropout rates were lower in DPT groups than comparators in the 14-RCT meta-analysis, indicating superior treatment compliance with no significant increase in adverse events
Methodology
This is a narrative mini-review published in Frontiers in Endocrinology (2025), drawing on a systematic literature search of PubMed, Web of Science, and Embase for English-language articles from January 2008 to May 2025. Priority was given to RCTs, meta-analyses, and systematic reviews; case reports, editorials, and non-peer-reviewed articles were excluded. The review synthesizes data from individual RCTs, a 14-RCT meta-analysis (n=978), and a network meta-analysis of 80 RCTs (n>6,900), but does not itself perform original statistical pooling.
Study Limitations
As a narrative mini-review, this paper is subject to selection bias and does not perform independent meta-analytic pooling, limiting the strength of its conclusions. The underlying RCTs show considerable heterogeneity in dextrose concentrations, injection frequencies, target sites, and follow-up durations, making definitive efficacy comparisons difficult. Most included trials have short follow-up periods and lack structural imaging endpoints; the authors acknowledge risk of bias across studies and the need for standardized, long-term RCTs. The study was funded by the Zhejiang Provincial Natural Science Foundation and the National Natural Science Foundation of China, with no declared commercial conflicts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.